Posted by: ctraderd | July 3, 2012

Vivus News Coming Soon

Vivus, Inc. (VVUS) has an obesity drug called Qnexa that has been approved by the NDA and has its PDUFA date set. On July 17, we will know if Qnexa has been approved or not. If Qnexa is approved, I could see the stock price going up a ton, but if the drug is rejected, the stock priced will probably go in the opposite direction.

Qnexa® (phentermine and topiramate) Extended-release Capsules is an investigational, once-per-day, weight-loss therapy that combines low doses of two agents approved by the Food and Drug Administration (FDA), phentermine and topiramate, in a controlled-release formulation.



VVUS’ Qnexa has two major competitors in the obesity drug industry, Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX). Arena Pharmaceuticals’ drug Belviq has already been approved and now has to go to the DEA. Orexigen’s next FDA trial will be sometime in 2014 with their drug Contrave.

Overall, we will have to see what the FDA’s ruling is on Qnexa.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s


%d bloggers like this: